Table 3.
Univariate analysis of factors for overall survival in patients with early stage pancreatic cancer, Kaplan-Meier method
| Factors | No. of patients (%) | Median OS [95% CI] | P value |
|---|---|---|---|
| Sex | .11 | ||
| Male | 32 (65.3%) | 12.0 [4.4–19.6] | |
| Female | 17 (34.7%) | 22.0 [10.1–33.9] | |
| Age | .47 | ||
| 75≥, and < 80 | 38 (77.6%) | 16.0 [10.0–22.0] | |
| ≥ 80 | 11 (22.4%) | 10.0 [5.5–14.5] | |
| BMI | .57 | ||
| < 25 | 43 (87.8%) | 13.0 [7.5–18.5] | |
| ≥ 25 | 6 (12.2%) | 19.0 [9.4–28.6] | |
| Smoking | .32 | ||
| Yes | 14 (29.8%) | 13.0 [5.2–20.8] | |
| No | 33 (70.2%) | 16.0 [10.2–21.8] | |
| Alcohol | .33 | ||
| Yes | 16 (34%) | 12.0 [0.3–23.8] | |
| No | 31 (66%) | 16.0 [10.7–21.3] | |
| HTN | .74 | ||
| Yes | 24 (50%) | 12.0 [6.0–18.0] | |
| No | 24 (50%) | 17.0 [6.1–27.9] | |
| DM | .58 | ||
| Yes | 22 (45.8%) | 9.0 [5.2–12.8] | |
| No | 26 (54.2%) | 10.9–23.1] | |
| Charlson comorbidity Index | .04 | ||
| 0 | 21 (42.9%) | 19.0 [12.5–25.5] | |
| 1 | 18 (36.7%) | 9.0 [0.7–17.3] | |
| 2 | 7 (14.3%) | 16.0 [5.7–26.3] | |
| 3 | 3 (6.1%) | 6.0 [4.4–7.6] | |
| ECOG | .18 | ||
| 0 | 11 (22.4%) | 22.0 [12.6–31.4] | |
| 1 | 32 (65.3%) | 14.0 [7.3–20.7] | |
| 2 | 4 (8.2%) | 5.0 [2.1–7.9] | |
| 3 | 2 (4.1%) | 6.0 | |
| Family hx. of malignancy | .27 | ||
| Yes | 7 (14.3%) | 9.0 [6.4–11.6] | |
| No | 42 (85.7%) | 16.0 [8.5–23.5] | |
| Location of tumor | .84 | ||
| Head | 12.0 [6.3–17.7] | ||
| Body & Tail | 19.0 [2.6–35.4] | ||
| Hb (g/dL) | .59 | ||
| ≥ 13 | 19 (38.8%) | 16.0 [6.2–25.8] | |
| < 13 | 30 (61.2%) | 13.0 [2.5–23.5] | |
| PT (INR) | .10 | ||
| ≤ 1.2 | 43 (93.5%) | 16.0 [8.6–23.4] | |
| > 1.2 | 3 (6.5%) | 9.0 [4.2–13.8] | |
| T. Bil | .92 | ||
| ≤ 1.2 | 32 (65.3%) | 16.0 [6.3–25.7] | |
| > 1.2 | 17 (34.7%) | 14.0 [10.2–17.9] | |
| Albumin (g/dL) | .55 | ||
| ≥ 3.3 | 45 (91.8%) | 16.0 [10.8–21.2] | |
| < 3.3 | 4 (8.2%) | 12.0 [0.0–24.0] | |
| CA 19–9 (U/mL) | .38 | ||
| ≤ 37 | 14 (29.2%) | 10.0 [8.3–11.8] | |
| > 37 | 34 (70.8%) | 16.0 [10.4–21.6] | |
| Stage | .12 | ||
| 1 | 5 (10.2%) | 22.5 [15.0–30.0] | |
| 2 | 44 (89.8%) | 13.0 [7.5–18.5] | |
| Surgical resection | .02 | ||
| Yes | 38 (77.6%) | 16.0 [5.1–26.9] | |
| No | 11 (22.4%) | 10.0 [4.6–15.4] | |
| CTx. and/or RTx. | .09 | ||
| Yes | 17 (34.7%) | 22.0 [8.6–35.4] | |
| No | 32 (65.3%) | 10.0 [4.6–15.4] |
No. number, OS overall survival, CI confidence interval, BMI body mass index, ECOG Eastern Cooperative Oncology Group, PS performance status, Hx. history, SD standard deviation, Hb hemoglobin, INR international normalized ratio, T. Bil total bilirubin, CA 19–9 carbohydrate antigen 19–9, CTx. chemotherapy, RTx. radiotherapy